Affimed NV Stock Price

0.00 (0.0%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Affimed NV AFMD NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Previous Close Last Traded
-0.18 -4.08% 4.23 4.23 4.50 4.42 4.41 18:35:01
Bid Price Ask Price Spread Spread % News
4.23 4.40 0.17 3.86% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
5,315 879,271 $ 4.40 $ 3,864,495 1,853,454 1.42 - 4.91
Last Trade Time Type Quantity Stock Price Currency
18:11:29 formt 1,350 $ 4.23 USD

Affimed NV Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 322.54M 76.25M 72.70M $ 24.00M $ - -0.56 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Affimed NV News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical AFMD Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week4.644.914.204.451,175,397-0.41-8.84%
1 Month2.994.912.884.281,569,3661.2441.47%
3 Months2.304.911.753.331,251,2951.9383.91%
6 Months2.764.911.422.781,077,1311.4753.26%
1 Year3.164.911.422.78866,8961.0733.86%
3 Years2.357.351.153.32819,1161.8880.0%
5 Years16.0724.201.153.55587,442-11.84-73.68%

Affimed NV Description

Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. The company is also developing single and combination therapies to treat cancers and other life-threatening diseases. Geographically, it derives a majority of revenue from the United States and also has a presence in Europe and Germany.

Your Recent History
Affimed NV
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.